Zobrazeno 1 - 7 of 7 pro vyhledávání: '"William, Barchuk"'
1
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)
Autor: Robert Landewé, Xenofon Baraliakos, Mikkel Østergaard, Chantal Tasset, Walter P. Maksymowych, R. Besuyen, Ke Liu, L. Gilles, Thijs Hendrikx, William Barchuk
Publikováno v: Rheumatology (Oxford, England), 61(5), 2063-2071. Oxford University Press
Maksymowych, W P, Østergaard, M, Landewé, R, Barchuk, W, Liu, K, Tasset, C, Gilles, L, Hendrikx, T, Besuyen, R & Baraliakos, X 2022, ' Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial) ', Rheumatology, vol. 61, no. 5, pp. 2063-2071 . https://doi.org/10.1093/rheumatology/keab543
Objective To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial. Methods Adults with active AS and inadequate resp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b0c62f663c80bf8343263f7c5c288c
https://doi.org/10.1093/rheumatology/keab543
Zobrazit plný text záznamu
2
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial
Autor: Mikkel Østergaard, William Barchuk, Thijs Hendrikx, R. Besuyen, Xenofon Baraliakos, L. Gilles, Ke Liu, Walter P. Maksymowych, Robert Landewé
Publikováno v: Rheumatology (United Kingdom), 61(6), 2388-2397. Oxford University Press
Maksymowych, W P, Østergaard, M, Landew, R, Barchuk, W, Liu, K, Gilles, L, Hendrikx, T, Besuyen, R & Baraliakos, X 2022, ' Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis : Results from the TORTUGA trial ', Rheumatology, vol. 61, no. 6, pp. 2388-2397 . https://doi.org/10.1093/rheumatology/keab758
Objectives To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial. Methods In the TORTUGA trial, patients with AS received filgotin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e53ef4c29e570478c08a5e43bffeefe6
https://doi.org/10.1093/rheumatology/keab758
Zobrazit plný text záznamu
3
Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study
Autor: Gary S. Firestein, David L. Boyle, Dion Chen, Cesar Calderon, Samuel E. DePrimo, Paul J. Dunford, Robin L. Thurmond, William Barchuk
Publikováno v: Inflammation Research. 68:261-274
In a double-blind, placebo-controlled, multiple-dose study, we assessed the molecular mechanism of action of the selective histamine-4-receptor antagonist toreforant. Patients with active rheumatoid arthritis (RA) despite methotrexate were randomized
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e8b30f6b6fd336d716960d37f8388c3
https://doi.org/10.1007/s00011-019-01218-y
Zobrazit plný text záznamu
4
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
Autor: Jeannie Chao, Ajay Nirula, Lai Shan Melanie Chan, Won Park, William Barchuk, Alan Kivitz, Jennifer Witcher, Anna Dudek, Alberto Spindler, Akira Sagawa, Mark C. Genovese
Publikováno v: The Journal of rheumatology. 48(7)
Objective.To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton’s tyrosine kinase in a 2-part, phase II trial (RAjuvenate; ClinicalTrials.gov: NCT02628028) in adults with active
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b526556b318f83fe4a47b58abcd89e60
https://pubmed.ncbi.nlm.nih.gov/33858981
Zobrazit plný text záznamu
5
SAT0089 SAFETY AND EFFICACY OF LY3337641, A BRUTON’S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY
Autor: Lai Shan (Melanie) Chan, Jeannie Chao, Anna Dudek, Ajay Nirula, Akira Sagawa, Alan Kivitz, William Barchuk, Mark C. Genovese, Alberto Spindler, Won Park
Publikováno v: SATURDAY, 15 JUNE 2019.
Background LY3337641 is an irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), a key signaling molecule in the B-cell-receptor and Fc-receptor pathways and mediator of B-cell– and myeloid-cell–dependent inflammatory arthritis.1,2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::748526a183f4c6ef17b38fdbb5af2543
https://doi.org/10.1136/annrheumdis-2019-eular.2672
Zobrazit plný text záznamu
6
Toreforant, an orally active histamine H
Autor: David L, Boyle, Samuel E, DePrimo, Cesar, Calderon, Dion, Chen, Paul J, Dunford, William, Barchuk, Gary S, Firestein, Robin L, Thurmond
Publikováno v: Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 68(4)
In a double-blind, placebo-controlled, multiple-dose study, we assessed the molecular mechanism of action of the selective histamine-4-receptor antagonist toreforant.Patients with active rheumatoid arthritis (RA) despite methotrexate were randomized
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ea403d20cfd479d8866d4897b89ed61b
https://pubmed.ncbi.nlm.nih.gov/30739130
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje